Urinary DNA Methylation Testing (Bladder EpiCheck®) and Its Peri-operative Kinetics for the Prediction of Residual Disease at Second Transurethral Resection in T1 Non-muscle-invasive Bladder Cancer (EPIRE)
Urinary DNA Methylation Testing (Bladder EpiCheck®) and Its Peri-operative Kinetics for the Prediction of Residual Disease at Second Transurethral Resection in T1 Non-muscle-invasive Bladder Cancer The EPIRE Study
European Association of Urology (EAU) guidelines mandate a second transurethral resection of bladder tumour (re-TURBt) for patients with high-grade or pT1 non-muscle-invasive bladder cancer (NMIBC) to eradicate residual disease and avoid understaging. However, 30% to 50% or more of patients undergoing re-TURBt have no residual tumour found upon re-resection, incurring surgical and anaesthetic risks, potential morbidity, healthcare costs, and delays in adjuvant therapy without direct oncological benefit.
Current non-invasive triage tools, such as urine cytology and office cystoscopy, suffer from low sensitivity or diagnostic ambiguity due to ongoing post-operative inflammation and tissue healing in a recently resected bladder. While novel molecular biomarkers like Bladder EpiCheck® demonstrate high sensitivity and negative predictive value in the surveillance setting, single-timepoint measurements shortly after resection struggle to differentiate transient, healing-induced epigenetic changes from true persistent malignancy.
Evaluating the longitudinal trajectory of the EpiScore across two distinct post-operative timepoints (T1 and T2) provides a physiological basis for distinguishing decaying inflammatory/reparative signals from stable or rising signals indicative of residual disease. Demonstrating the diagnostic accuracy of Bladder EpiCheck® at T2, alongside the dynamic change in EpiScore (ΔEpiScore), will establish whether non-invasive urine biomarker testing can reliably select low-risk pT1 NMIBC patients in whom re-TURBt can be safely omitted.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Gian Luca De Salvo, MD
- Telefonnummer: 0498215704
- E-post: clinical.trial@iov.veneto.it
Studer Kontakt Backup
- Navn: Antonio Amodeo, MD
- Telefonnummer: 0423421321
- E-post: antonio.amodeo@iov.veneto.it
Studiesteder
-
-
Italy/Padova
-
Padova, Italy/Padova, Italia, 35128
- Istituto Oncologico Veneto
-
Ta kontakt med:
- Antonio Amodeo, MD
- Telefonnummer: 0423421321
- E-post: antonio.amodeo@iov.veneto.it
-
Ta kontakt med:
- Francesco Claps, MD
- Telefonnummer: 0423421321
- E-post: francesco.claps@iov.veneto.it
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- age ≥18 years;
- histologically confirmed pT1 urothelial carcinoma of the bladder (any grade, WHO 2022 and 1973 classifications) on the definitive histology of the initial TURBt;
- macroscopically complete initial resection as reported by the surgeon, with detrusor muscle present in the specimen, both formally documented in the operative and pathology records;
- indication for second TURBt according to EAU guidelines, with the procedure scheduled at the study centre and expected within ten weeks of the initial TURBt;
- clinically localised non-metastatic disease (cN0, cM0);
- patients able to provide written informed consent.
- Previous BCG treatment is allowed.
Exclusion Criteria:
- muscle-invasive disease (≥pT2) on the definitive histology of the initial TURBt;
- initial resection judged incomplete by the operating surgeon - whether because visible tumour was deliberately left behind or because the procedure had to be curtailed and a planned second look arranged - or absence of detrusor muscle in the specimen - these patients receive second TURBt per guidelines but are outside the study question, which concerns the completely resected patient;
- pure non-urothelial histology (primary adenocarcinoma, pure squamous cell carcinoma, small cell neuroendocrine carcinoma, sarcoma). Variant histologies of urothelial carcinoma are not an exclusion criterion but are recorded as a covariate;
- concomitant upper tract urothelial carcinoma, or a history of it within the preceding 24 months, given the documented positivity of Bladder EpiCheck® in that disease [19];
- A single early post-operative chemotherapy instillation, where given, is not an exclusion criterion but is recorded as a covariate;
- previous pelvic radiotherapy;
- indwelling urinary catheter or intermittent self-catheterisation; urinary diversion or neobladder;
- clinically non-localised disease (cN+, cM+);
- pregnancy or breastfeeding;
- TURBt performed in an emergency setting for uncontrolled bleeding or other life-threatening indication, in which resection quality cannot be assured;
- second TURBt not performed at the study centre, with consequent unavailability of the reference standard;
- patients unable to provide written informed consent, or any condition that in the investigator's judgement compromises the ability to comply with study procedures.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: EPIRE
|
The investigational IVD medical device evaluated as the index test is the Bladder EpiCheck® system (manufactured by Nucleix Ltd.; exclusive Italian distributor: A. Menarini Diagnostics s.r.l.). The assay is CE-IVD marked under Directive 98/79/EC (Annex III, General IVD category) and cleared by the US FDA via the 510(k) pathway. The manufacturer operates under a certified UNI CEI EN ISO 13485:2016 quality management system. Bladder EpiCheck® profiles the DNA methylation patterns of 15 proprietary DNA biomarkers on genomic DNA isolated from the cellular pellet of a voided urine sample. The assay protocol involves DNA extraction, digestion with a methylation-sensitive restriction enzyme, and subsequent multiplex real-time polymerase chain reaction (multiplex real-time PCR). Dedicated analysis software generates a quantitative integrative score termed the EpiScore, on a continuous scale from 0 to 100. In accordance with the manufacturer's Instructions for Use (IFU), the qualitative diagno |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Diagnostic accuracy of Bladder EpiCheck® test at timepoint T2 for residual disease at second TURBt in T1 NMIBC patients.
Tidsramme: Through study completion, an average of 2 years
|
Diagnostic accuracy of EpiScore at T2 (categorized as > 60 positive vs ≤ 60 negative) evaluated against central histopathology review of the second TURBt, measured as Sensitivity, Specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV), Accuracy, and Likelihood Ratios. |
Through study completion, an average of 2 years
|
|
Diagnostic accuracy of change EpiScore between the two subsequent timepoints T1 and T2.
Tidsramme: Through study completion, an average of 2 years
|
Average daily rate of change in EpiScore, calculated as ∆EpiScore=(T2-T1)/(Days between T1 and T2) evaluated against second TURBt residual disease status using a univariate logistic regression model and Area Under the ROC Curve (AUC) with 95% CI. |
Through study completion, an average of 2 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Diagnostic accuracy of Bladder EpiCheck® test at timepoint T1
Tidsramme: Through study completion, an average of 2 years
|
Sensitivity, Specificity, PPV, NPV, Accuracy, and Likelihood Ratios (95% CI) of EpiScore at T1 (> 60 vs ≤ 60) for residual disease at second TURBt |
Through study completion, an average of 2 years
|
|
Diagnostic accuracy of urinary cytology at timepoints T1 and T2
Tidsramme: Through study completion, an average of 2 years
|
Sensitivity, Specificity, PPV, NPV, Accuracy, and Likelihood Ratios (95% CI) of urinary cytology (Paris System classification) at T1 and T2 against second TURBt histopathology |
Through study completion, an average of 2 years
|
|
Agreement at T1 and T2 between Bladder EpiCheck® and urinary cytology
Tidsramme: Through study completion, an average of 2 years
|
Concordance between Bladder EpiCheck® and urinary cytology at T1 and T2, quantified by Cohen's kappa (κ) coefficient. |
Through study completion, an average of 2 years
|
|
Agreement between T1 and T2 of Bladder EpiCheck®;
Tidsramme: Through study completion, an average of 2 years
|
Agreement on paired aliquots of Bladder EpiCheck® between timepoints T1 and T2 with McNemar's test for paired data |
Through study completion, an average of 2 years
|
|
Agreement between T1 and T2 of urinary cytology
Tidsramme: Through study completion, an average of 2 years
|
Agreement on paired aliquots of urinary cytology between timepoints T1 and T2 with McNemar's test for paired data |
Through study completion, an average of 2 years
|
|
Diagnostic accuracy at T1 and T2 of the combination of Bladder EpiCheck® and urinary cytology, defined in two versions: (1) as negative when both are negative, (2) as negative when at least one is negative
Tidsramme: Through study completion, an average of 2 years
|
Sensitivity, Specificity, PPV, NPV, and Accuracy at T1 and T2 evaluated under two combination definitions: (1) negative when both tests are negative; (2) negative when at least one test is negative |
Through study completion, an average of 2 years
|
|
Diagnostic accuracy in the previous settings for predicting high-grade disease, ≥ pT1, and/or concomitant Carcinoma in Situ (CIS) at second TURBt;
Tidsramme: Through study completion, an average of 2 years
|
Diagnostic accuracy measures (Sensitivity, Specificity, PPV, NPV) of tests and combinations specifically for predicting high-grade disease, ≥ pT1, and/or concomitant Carcinoma in Situ (CIS) at second TURBt |
Through study completion, an average of 2 years
|
|
Diagnostic accuracy of alternative definitions of change in EpiScore
Tidsramme: Through study completion, an average of 2 years
|
Diagnostic accuracy and AUC for alternative definitions of Episcore change between T1 and T2: absolute difference (T2-T1) and relative percentage change (T2-T1)/T1; |
Through study completion, an average of 2 years
|
|
Change in positivity rate of Bladder EpiCheck® and urinary cytology between T1 and T2 among patients whose second TURBt is negative.
Tidsramme: Through study completion, an average of 2 years
|
9) Proportion of test positivity change between T1 and T2 in patients without residual disease (measuring the clearance rate of post-operative false positives). |
Through study completion, an average of 2 years
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Mannlige urogenitale sykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Neoplasmer etter histologisk type
- Neoplasmer, kjertel og epitel
- Urologiske neoplasmer
- Karsinom
- Urinblæresykdommer
- Neoplasmer i urinblæren
- Ikke-muskelinvasive blære-neoplasmer
Andre studie-ID-numre
Andre studie-ID-numre
- IOV-NMIBC-02-2026-EPIRE
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .